RRM1单核苷酸多态性与非小细胞肺癌患者对吉西他滨化疗敏感性的相关性研究

发布时间：2019-05-11 05:05

【摘要】：目的:探讨核苷酸还原酶M1亚基(RRM1)的单核苷酸多态性(SNPs)与非小细胞肺癌(NSCLC)患者对吉西他滨化疗敏感性的相关性。方法:选取2014年8月-2016年7月我院NSCLC初治患者96例,均接受以吉西他滨为基础的两药联合化疗方案,连续化疗至少2个周期(每28 d为1个周期)。以完全缓解、部分缓解的患者总数与受试患者总数的比值来计算化疗敏感率;采用聚合酶链反应和直接测序法检测其RRM1基因型;分析患者不同基因型与化疗敏感性的相关性。结果:RRM1-37CA的CC、CA、AA基因型分布频率分别为35.42%、52.08%、12.50%,-524CT的CC、CT、TT基因型分布频率分别为18.75%、37.50%、43.75%,各基因型分布频率均符合Hardy-Weinberg平衡(P0.05)。96例NSCLC患者的化疗敏感率为37.50%。患者的年龄、性别、民族、吸烟与否、TNM分期、病理类型、化疗方案和美国东部肿瘤协作组评分与化疗敏感性无关(P0.05)。RRM1(-37CA)+(-524CT)、(-37CC)+(-524TT)基因型患者的化疗敏感率(57.14%、39.39%)均显著高于其他基因型患者(10.71%),差异均有统计学意义(P0.05);而RRM1(-37CA)+(-524CT)与(-37CC)+(-524TT)基因型患者的化疗敏感率比较,差异无统计学意义(P0.05)。结论:NSCLC患者RRM1的SNPs可作为评价吉西他滨化疗敏感性的预测因子,RRM1(-37CA)+(-524CT)和(-37CC)+(-524TT)基因型患者对该类化疗方案具有更高的敏感性。
[Abstract]:Aim: to investigate the relationship between single nucleotide polymorphism (SNPs) of nucleotidyl reducase M1 subunit (RRM1) and chemotherapy sensitivity of patients with non-small cell lung cancer (NSCLC) to gemcitabine. Methods: from August 2014 to July 2016, 96 patients with NSCLC in our hospital were treated with gemcitabine combined chemotherapy for at least two cycles (1 cycle every 28 days). The chemotherapy sensitivity rate was calculated by the ratio of the total number of patients with complete remission and partial remission to the total number of patients tested, the RRM1 genotype was detected by polymerase chain reaction (PCR) and direct sequencing, and the correlation between different genotypes and chemotherapy sensitivity was analyzed. Results: the frequency of CC,CA,AA genotype distribution of RRM1-37CA was 35.42%, 52.08%, 12.50%, 18.75%, 37.50% and 43.75%, respectively. The distribution frequency of each genotype was in accordance with Hardy-Weinberg balance (P 0.05). The chemotherapy sensitivity rate of 96 patients with NSCLC was 37.50%. The age, sex, nationality, smoking or not, TNM stage, pathological type, chemotherapy regimen and the score of tumor cooperation group in the eastern United States were not related to chemotherapy sensitivity (P 0.05). RRM1 (- 37CA) (- 524CT), The chemotherapy sensitivity rate of (- 37CC) (- 524TT) genotypic patients (57.14%, 39.39%) was significantly higher than that of other genotypic patients (10.71%), the difference was statistically significant (P 0.05). However, there was no significant difference in chemotherapy sensitivity rate between RRM1 (- 37CA) (- 524CT) and (- 37CC) (- 524TT) genotypic patients (P 0.05). Conclusion: SNPs of RRM1 in patients with NSCLC can be used as a predictor of gemcitabine chemotherapy sensitivity. RRM1 (- 37CA) (- 524CT) and (- 37CC) (- 524TT) genotypic patients are more sensitive to this kind of chemotherapy regimen.
【作者单位】：石河子大学医学院第一附属医院肿瘤内科;
【基金】：国家自然科学基金资助项目(No.81560381)
【分类号】：R734.2

【相似文献】